Presenting their findings at a recent European Science Foundation (ESF) and European Cooperation in the field of Scientific and Technical Research (COST) conference, scientists show how new food technologies are changing European diets.

The industrial revolution brought the advent of modern food processing technology. Whether you credit the Frenchman Nicholas Appert in 1809, or British born Peter Durand in 1810, the invention of the tin can has revolutionised the way people eat. The motivation behind its invention was simple “ make food last long. Two hundred years on, food scientists are still trying to improve the shelf life of food.

For example, by introducing mixtures of oxygen, nitrogen and carbon dioxide into packaging, some fresh vegetables have had their life extended two- or three-fold. A similar approach is used in the packaging of meat, where gas is pumped into packaging, reducing oxygenation of the meats pigments, extending its shelf life.

But today's food scientists have to consider more than just the use-by-date. Europeans want food that is cheap, convenient, high quality, safe and more and more produced in a eco-friendly way, explains Professor Brian McKenna, a food scientist at University College Dublin in Ireland. In addition, McKenna thinks that food plays a variety of roles in European society nowadays. Food is important to peoples health as it is increasingly being linked to diseases such as obesity, coronary heart disease and diabetes, he says. Furthermore, Europeans are now more aware of the cultural role of food in every day life. So food scientists must design technology that helps people get what they want from their food.

While increased interest over food can deliver more choice for consumers, it has also led to some misinformed debates. And Europeans have resisted many potentially useful technologies over unsubstantiated fears that they are not safe. Nowadays, the public are much more sceptical, particularly when it come to food, says McKenna. McKenna cites the example of using irradiation to kill pests and increase the shelf-life of mushrooms. But this process is confined to only a few countries within Europe, such as the Netherlands, despite a considerable amount of evidence that it is safe for humans.

McKenna thinks that food scientists must consider the public's perception of new technologies or risk the rejection of these technologies. One example is nanotechnology ”engineering at a very small scale. Nanotechnology is being used in medicine to deliver drugs to specific targets in the body. A similar approach could be used in food to deliver vitamins. However, there are currently no foods using nano-particles in this way in Europe. The use of nanotechnology in food has been slow because of public concern that nano-ingredients could reach parts of the body where they were never intended.

McKenna hopes that by understanding the socioeconomic, political, and cultural influences on what Europeans eat, food scientists can better advise policy makers about how food should be processed and packaged, and how it is sold and eventually eaten.

The conference, on November 5-6, was attended by 75 scientists and policy makers from 22 countries and was one of the series of research conferences organised by the ESF-COST Forward Look initiative. Forward Look, a flagship instrument of the ESF, allows scientists to meet people from the world of policy and help set priorities for future research.

esf/

Over the past decade, Takeda has furthered their commitment to people living with type 2 diabetes and pursued the development of alogliptin, an investigational DPP-4 inhibitor. ACTOS and alogliptin have distinct but complementary mechanisms of action, addressing insulin resistance and insulin deficiency, and potentially providing patients with multiple monotherapy and combination therapy options.

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS, a prescription medication, is taken once daily as an adjunct to diet and exercise, and is approved for use for type 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas, or metformin.

Important Safety Information About ACTOS?® (pioglitazone HCl)

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause or worsen congestive heart failure. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath.

Do not take ACTOS if you have active liver disease. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin. If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase your chance of becoming pregnant. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs and ankles, and anemia. Some people, particularly women, are at higher risk of having bone fractures while taking ACTOS. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Very rarely, some patients have experienced visual changes while taking ACTOS.

http:www.tgrd/